

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
202788Orig1s000

MICROBIOLOGY REVIEW(S)

Product Quality Microbiology Review

7 SEPTEMBER 2011

NDA: 202788

Drug Product Name

Proprietary: N/A

Non-proprietary: Fentanyl Sublingual Spray

Review Number: 1

Dates of Submission(s) Covered by this Review

Submit	Received	Review Request	Assigned to Reviewer
4 March 2011	4 March 2011	18 April 2011	21 April 2011
5 August 2011	5 August 2011	N/A	N/A

Submission History (for amendments only): N/A

Applicant/Sponsor

Name: Insys Therapeutics, Inc.

Address: 10220 S. 51st Street, Suite 2, Phoenix, AZ 85044


Representative: Lauren H. Wind, MPH, Senior Consultant (The Weinberg Group Inc.)

Telephone: 202-730-4101

Name of Reviewer: Bryan S. Riley, Ph.D.

Conclusion: Recommended for Approval

Product Quality Microbiology Data Sheet

- A. 1. **TYPE OF SUBMISSION:** 505(b)(2) NDA
2. **SUBMISSION PROVIDES FOR:** A sublingual drug product
3. **MANUFACTURING SITE:**  (b) (4)
4. **DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:**  (b) (4) solution in a glass vial with rubber stopper, in a single-dose sublingual spray apparatus, 100, 200, 400, 600, and 800 mcg/dose.
5. **METHOD(S) OF STERILIZATION:** N/A
6. **PHARMACOLOGICAL CATEGORY:** Opioid analgesic
- B. **SUPPORTING/RELATED DOCUMENTS:** N/A
- C. **REMARKS:** This was an eCTD submission. The following IR was sent to the applicant on 1 August 2011 – “Provide descriptions of the test methods used for microbial limits. Also provide a summary of the microbiological method suitability testing with the drug product.” The response to the IR was provided in an amendment dated 5 August 2011. The amendment was reviewed in section P.5 of this review.

filename: N202788R1.doc

Executive Summary

I. Recommendations

- A. Recommendation on Approvability** – This submission is recommended for approval on the basis of product quality microbiology.
- B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable** – N/A

II. Summary of Microbiology Assessments

- A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology** – (b) (4)
- B. Brief Description of Microbiology Deficiencies** – N/A
- C. Assessment of Risk Due to Microbiology Deficiencies** – N/A

III. Administrative

- A. Reviewer's Signature** _____
Bryan S. Riley, Ph.D.
Senior Review Microbiologist, OPS/NDMS
- B. Endorsement Block** _____
Stephen E. Langille, Ph.D.
Senior Review Microbiologist, OPS/NDMS
- C. CC Block**
N/A

4 Page(s) has been Withheld in Full as B4 (CCI/TS) immediately following this page

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BRYAN S RILEY
09/07/2011

STEPHEN E LANGILLE
09/07/2011

PRODUCT QUALITY MICROBIOLOGY FILING CHECKLIST

NDA Number: 202788

Applicant: Insys Therapeutics, Inc. **Letter Date:** 4 March 2011

Drug Name: Fentanyl Sublingual Spray

NDA Type: 505(b)(2)

Stamp Date: 4 March 2011

The following are necessary to initiate a review of the NDA application:

	Content Parameter	Yes	No	Comments
1	Is the product quality microbiology information described in the NDA and organized in a manner to allow substantive review to begin? Is it legible, indexed, and/or paginated adequately?	X		The submission is in the eCTD format.
2	Has the applicant submitted an overall description of the manufacturing processes and microbiological controls used in the manufacture of the drug product?	X		
3	Has the applicant submitted protocols and results of validation studies concerning microbiological control processes used in the manufacture of the drug product?	X		
4	Are any study reports or published articles in a foreign language? If yes, has the translated version been included in the submission for review?		X	
5	Has the applicant submitted preservative effectiveness studies (if applicable) and container-closure integrity studies?		X	The drug product is a (b) (4) sublingual spray in a unit-dose container. (b) (4) studies are not required.
6	Has the applicant submitted microbiological specifications for the drug product and a description of the test methods?	X		
7	Has the applicant submitted the results of analytical method verification studies?		X	
8	Has the applicant submitted all special/critical studies/data requested during pre-submission meetings and/or discussions?	X		
9	Is this NDA fileable? If not, then describe why.	X		

Additional Comments: N/A

3 May 2011

Bryan S. Riley, Ph.D.
Senior Review Microbiologist

Date

Stephen E. Langille, Ph.D.
Senior Review Microbiologist

Date

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BRYAN S RILEY
05/04/2011

STEPHEN E LANGILLE
05/04/2011